pI: 9.3484 |
Length (AA): 724 |
MW (Da): 80516 |
Paralog Number:
3
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 10 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
124 | 501 | 1n6m (B) | 299 | 668 | 30.00 | 0 | 1 | 0.56 | 0.09 |
180 | 496 | 1v8k (A) | 69 | 395 | 53.00 | 0 | 1 | 1.01 | -1.18 |
183 | 537 | 1sdm (A) | 889 | 1252 | 33.00 | 0 | 1 | 0.73 | -0.75 |
183 | 501 | 2h58 (A) | 445 | 766 | 37.00 | 0 | 1 | 0.9 | -1.19 |
2 | 64 | 5j8y (C) | 1142 | 1203 | 18.00 | 0 | 0.75 | 0.501817 | -1.99 |
2 | 62 | 2k4p (A) | 26 | 86 | 25.00 | 0 | 1 | 0.552054 | -1.41 |
3 | 61 | 4nl9 (A) | 9 | 66 | 31.00 | 0.31 | 0.89 | 0.598292 | -1.66 |
4 | 69 | 1b0x (A) | 915 | 980 | 17.00 | 0.0013 | 1 | 0.55096 | -2.28 |
183 | 533 | 5mio (C) | 258 | 646 | 55.00 | 0 | 1 | 1.14361 | -0.8 |
656 | 723 | 5j2l (B) | 4 | 71 | 9.00 | 0.51 | 0 | 0.240723 | -0.95 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_127200)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G16630 | kinesin 13A |
Arabidopsis thaliana | AT3G16060 | ATP binding microtubule motor family protein |
Babesia bovis | BBOV_II007750 | kinesin-like protein, putative |
Brugia malayi | Bm1_42920 | Kinesin motor domain containing protein |
Caenorhabditis elegans | CELE_K11D9.1 | Protein KLP-7, isoform B |
Cryptosporidium hominis | Chro.80383 | kinesin-like protein |
Cryptosporidium parvum | cgd8_3300 | centromere associated Kip3p, kinesin like P-loop NTpase that belongs to the TRAFAC class GTpase superfamily |
Dictyostelium discoideum | DDB_G0267404 | SAM domain-containing protein |
Drosophila melanogaster | Dmel_CG1453 | Kinesin-like protein at 10A |
Echinococcus granulosus | EgrG_001159400 | kinesin protein KIF2A |
Echinococcus granulosus | EgrG_001118400 | kinesin protein KIF2A |
Echinococcus multilocularis | EmuJ_001118400 | kinesin protein KIF2A |
Echinococcus multilocularis | EmuJ_001159400 | kinesin protein KIF2A |
Giardia lamblia | GL50803_16945 | Kinesin-13 |
Homo sapiens | ENSG00000186638 | kinesin family member 24 |
Homo sapiens | 3796 | kinesin heavy chain member 2A |
Homo sapiens | ENSG00000142945 | kinesin family member 2C |
Homo sapiens | ENSG00000141200 | kinesin family member 2B |
Leishmania braziliensis | LbrM.01.0060 | MCAK-like kinesin, putative |
Leishmania braziliensis | LbrM.13.1470 | MCAK-like kinesin, putative |
Leishmania donovani | LdBPK_010030.1 | Kinesin-13 1, putative |
Leishmania donovani | LdBPK_131350.1 | Kinesin-13 5, putative |
Leishmania infantum | LinJ.01.0030 | MCAK-like kinesin, putative |
Leishmania infantum | LinJ.13.1350 | MCAK-like kinesin, putative |
Leishmania major | LmjF.13.1610 | MCAK-like kinesin, putative |
Leishmania major | LmjF.01.0030 | MCAK-like kinesin, putative |
Leishmania mexicana | LmxM.01.0030 | MCAK-like kinesin, putative |
Leishmania mexicana | LmxM.13.1610 | MCAK-like kinesin, putative |
Mus musculus | ENSMUSG00000046755 | kinesin family member 2B |
Mus musculus | ENSMUSG00000028678 | kinesin family member 2C |
Mus musculus | ENSMUSG00000028438 | kinesin family member 24 |
Mus musculus | ENSMUSG00000021693 | kinesin family member 2A |
Neospora caninum | NCLIV_013810 | hypothetical protein |
Oryza sativa | 4337845 | Os05g0154700 |
Oryza sativa | 4326684 | Os01g0625200 |
Plasmodium berghei | PBANKA_1458300 | kinesin-13, putative |
Plasmodium falciparum | PF3D7_1245100 | kinesin-13, putative |
Plasmodium knowlesi | PKNH_1464800 | kinesin-13, putative |
Plasmodium vivax | PVX_101150 | kinesin-13, putative |
Plasmodium yoelii | PY07317 | kinesin homolog-related |
Plasmodium yoelii | PY03174 | kinesin-like protein K6 |
Schistosoma japonicum | Sjp_0022180 | ko:K10393 kinesin family member 2/24, putative |
Schistosoma mansoni | Smp_002280 | hypothetical protein |
Schmidtea mediterranea | mk4.000194.14 | Kinesin like protein |
Schmidtea mediterranea | mk4.005044.01 | Kinesin-like protein Klp10A |
Schmidtea mediterranea | mk4.000194.13 | Kinesin-like protein Klp10A |
Schmidtea mediterranea | mk4.000194.10 | |
Schmidtea mediterranea | mk4.000194.12 | Kinesin-like protein Klp10A |
Schmidtea mediterranea | mk4.003054.02 | Kinesin-like protein Klp10A |
Schmidtea mediterranea | mk4.000194.11 | |
Schmidtea mediterranea | mk4.005044.03 | Kinesin like protein |
Schmidtea mediterranea | mk4.003054.05 | Kinesin like protein |
Schmidtea mediterranea | mk4.003054.01 | |
Trypanosoma brucei gambiense | Tbg972.11.3650 | MCAK-like kinesin, putative |
Trypanosoma brucei gambiense | Tbg972.9.1890 | MCAK-like kinesin, putative |
Trypanosoma brucei | Tb927.9.3650 | Kinesin-13 1 |
Trypanosoma brucei | Tb927.11.3280 | Kinesin-13 5, putative |
Trypanosoma congolense | TcIL3000_9_1140 | Kinesin-13 1, putative |
Trypanosoma congolense | TcIL3000.11.3100 | Kinesin-13 5, putative |
Trypanosoma cruzi | TcCLB.509589.30 | Kinesin-13 5, putative |
Trypanosoma cruzi | TcCLB.503999.20 | Kinesin-13 5, putative |
Trypanosoma cruzi | TcCLB.506895.40 | Kinesin-13 1, putative |
Trypanosoma cruzi | TcCLB.508501.290 | Kinesin-13 1, putative |
Toxoplasma gondii | TGME49_287160 | internal kinesin motor domain protein |
Theileria parva | TP02_0685 | kinesin, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.02.0790 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.0790 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.0790 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.02.0790 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb09.160.2260 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.160.2260 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.160.2260 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb09.160.2260 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_K11D9.1 | Caenorhabditis elegans | embryonic lethal | wormbase |
PBANKA_1458300 | Plasmodium berghei | Essential | plasmo |
TGME49_287160 | Toxoplasma gondii | Probably essential | sidik |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3